Results 31 to 40 of about 12,259 (202)
Bromocriptine in Parkinsonism [PDF]
BMJ, 1974 Bromocriptine, a drug acting directly upon dopaminergic receptors, has been found to have a significant therapeutic action in a double-blind study of 20 patients with idiopathic Parkinsonism who were already receiving conventional therapy, including levodopa.
D B, Calne +5 more
openaire +2 more sources
THE EFFECT OF BROMOCRIPTINE ON C-REACTIVE PROTEIN IN WOMEN WITH HYPERPROLACTINEMIC AMENORRHEA [PDF]
The Medical Journal of Basrah University, 2008 C-reactive protein has become the subject of avid interest in recent years. Increased concentrations of C-reactive protein (CRP) became widely accepted as a risk factor of many inflammatory diseases including atherosclerosis, ischemic vascular diseases ...
Isam Hamo Mahmood
doaj +1 more source
BMC Endocrine Disorders, 2020 Background Whether lower dose cabergoline therapy for hyperprolactinemia increases risk of valvular dysfunction remains controversial. We examined valvular abnormalities among asymptomatic adults with hyperprolactinemia treated with dopamine agonists ...
Amer Budayr +6 more
doaj +1 more source
Current Therapeutic Research, 2021 : Background: Although dopamine D2 receptor agonists, bromocriptine and cabergoline, are notable medications in the treatment of Parkinsonism, hyperprolactinemia, and hyperglycemia, there is an identified relationship between the utilization of D2-like ...
Mohammed Fouad Shalaby, MD +5 more
doaj +1 more source
Journal of Diabetes Investigation, 2021 Dopamine receptor agonists are typically used to treat Parkinson’s disease and certain pituitary tumors, such as prolactinoma or a growth hormone‐producing tumor.
Motoyuki Igata +8 more
doaj +1 more source
Diabetology & Metabolic Syndrome, 2023 Background Type 2 diabetes (T2DM) patients, including those in good glycemic control, have an increased risk of cardiovascular disease (CVD). Maintaining good glycemic control with drugs may reduce long-term CVD risk.
Mulualem Tesfaye Birhan +3 more
doaj +1 more source
Effects of Bromocriptine on Glucose and Insulin Dynamics in Normal and Insulin Dysregulated Horses
Frontiers in Veterinary Science, 2022 The objectives of the study were to study the effects of the synthetic ergot alkaloid (EA), bromocriptine, on glucose and lipid metabolism in insulin dysregulated (ID, n = 7) and non-ID (n = 8) mares. Horses were individually housed and fed timothy grass
Caroline M. M. Loos +6 more
doaj +1 more source
Endocrinology, Diabetes & Metabolism, 2020 Objective Sympathetic nervous system (SNS) overactivity is a risk factor for insulin resistance and cardiovascular disease (CVD). We evaluated the impact of bromocriptine‐QR, a dopamine‐agonist antidiabetes medication, on elevated resting heart rate (RHR)
Bindu Chamarthi +3 more
doaj +1 more source
Dopaminergic agonist bromocriptin in treatment of diabetes mellitus type 2
Ожирение и метаболизм, 2011 Bromocriptine is a sympatholytic agonist of dopamine receptors, which is now proposed for treatment of type 2 diabetes mellitus. In animal studies bromocriptine elevates the decreased levels of dopamine in hypothalamus and blocks excessive sympathetic ...
O. A. Gerasimenko +2 more
doaj +1 more source
BMC Pharmacology and Toxicology, 2021 Background Dopamine D2 receptor agonists, bromocriptine and cabergoline, are notable medications in the treatment of Parkinsonism, hyperprolactinemia, and hyperglycemia.
Mohammed Ahmed Fouad Shalaby +6 more
doaj +1 more source